Christoph Boss, Ph.D.

Vice President, Medicinal Chemistry

Christoph Boss, Ph.D. brings an impressive track record with multiple patents, publications, and two decades of experience in medicinal chemistry. He is a dedicated drug hunter and enjoys teamwork and collaboration.

Christoph started his career at Actelion Pharmaceuticals Ltd and worked his way up through the ranks taking on roles of increased responsibility to ultimately lead the Oncology Chemistry teams. In 2017, Actelion was acquired by Johnson & Johnson and Christoph became part of the newly formed Idorsia Pharmaceuticals at which time he was promoted to Senior Vice President, Head of Drug Discovery Chemistry. Shortly after, Christoph received the SCS Industrial Science Award from the Swiss Chemical Society, he sits as a council member of the FHNW Foundation, and the Foundation of Swiss Chemical Society in efforts to impart his knowledge and experience on younger chemists.

Some of his key contributions include being a co-inventor of Macitentan, marketed today by Johnson and Johnson as Opsumit® for the treatment of pulmonary hypertension and Aprocitentan, another endothelin receptor antagonist which successfully finished Phase 3 clinical trials and is currently under FDA review for the treatment of difficult types of hypertensions. He was a key player in the identification of Daridorexant, a dual orexin receptor antagonist known as Quviviq® marketed by Idorsia Pharmaceuticals Ltd for the treatment of insomnia disorder.

Christoph has a Ph.D. in synthetic organic chemistry from The University of Bern, Switzerland and then went on to complete postdoctoral work at The Scripps Research Institute in La Jolla, California under the supervision of Professor Julius Rebek, Jr.